Australia's Paradigm jumps most in over 4 mths on upbeat knee-pain drug data

Hanall Biopharma

03/02/2021 02:55

** Shares of Paradigm Biopharmaceuticals Ltd  PAR.AX  gain
as much as 10.8% to A$2.760; their biggest intraday pct jump
since Sept. 29
    ** The biopharma co reports additional data on 13 patients
receiving its phase 3 injectable drug Zilosul for knee pain due
to Osteoarthritis  urn:newsml:reuters.com:*:nASX35t2cV
    ** Says the average chronic knee pain reduction in patients
increased to 49.6% from the previously reported 47.3%
 urn:newsml:reuters.com:*:nL4N2GS0WJ
    ** PAR shares at their highest level since Dec. 9 on its
second straight session of gains
    ** Volumes are over thrice the 30-day avg at about 19.4 mln
shares
    ** Stock has lost 2.4% this year as of last close

 (Reporting by Yamini C S)
 ((Yamini.CS@thomsonreuters.com;))